BridgeBio has substantially boosted this development of a new treatment for cardiac amyloidosis, employing the compound. Preliminary trial information indicates significant outcomes for patients diagnosed by this https://attrcm008416.blogdiloz.com/40651225/company-advances-amyloidosis-therapy-with-attruby